RecruitingNot applicableNCT06202248

A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alpha Tau Medical LTD.
Principal Investigator
Tomer Charas, MD
Radiotherapy unit at Rambam Health Care Campus, Israel
Intervention
Experimental: DaRT seeds(device)
Enrollment
10 enrolled
Eligibility
18-120 years · MALE
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06202248 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia

← Back to all trials